Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Bridget Keenan, PhD
Headshot of Bridget Keenan
Bridget Keenan

Description

Summary

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D(Refered Phase II dose) of ATG-031.

Official Title

A First-in-Human Phase I Study of ATG-031 in Patients With Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Details

This is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase. Dose Escalation Phase: approximately 30-48 patients . Dose Expansion Phase: the number of patients enrolled will depend on the number of disease cohorts to be expanded and data observed in the Dose Escalation Phase.The Dose Escalation Phase will enroll patients with advanced solid tumors. Based on data from dose escalation (e.g., adverse events [AEs], dose-limiting toxicity [DLT], efficacy data, pharmacodynamic [PDx] data, or pharmacokinetic [PK] data), the Dose Expansion Phase will enroll patients with selected advanced solid tumors or B-NHL.

Keywords

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas, ATG-031, solid tumor, CD 24, Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Histological or cytologically confirmed advanced solid tumor or B-NHL which have relapsed from or been refractory to all locally available standard therapies.
  2. Adequate hepatic function:
    1. AST and ALT ≤ 2.5×times ULN (≤ 5 × ULN if liver metastases).
    2. Total bilirubin ≤ 1.5×ULN (except Gilbert syndrome).
    3. Lipase and amylase ≤ 2×ULN.
  3. Adequate renal function: calculated creatinine clearance of ≥ 40 mL/min using the Cockroft- Gault formula.
  4. Adequate bone marrow function without growth factors or blood transfusion within 7 days of the first dose of study treatment.
    1. Absolute neutrophil count (ANC) ≥ 1.5×109/L.
    2. Platelet count ≥ 100×109/L.
    3. Hemoglobin ≥ 90 g/L.

You CAN'T join if...

  1. Patients with CNS malignancies, except those who are clinically stable for ≥ 4 weeks and off corticosteroids following prior surgery, whole-brain radiation, or stereotactic radiosurgery.
  2. Received any other investigational product or prior systemic anticancer therapy including chemotherapy, immunotherapy, radiotherapy, or other anticancer within 21 days prior to first dose of study
  3. Grade ≥3 irAEs or irAEs that lead to discontinuation of prior immunotherapy.8. Other primary malignancies developed within 5 years prior to the first dose of the study treatment
  4. Other primary malignancies developed within 5 years prior to the first dose of the study treatment
  5. Have active or previous autoimmune diseases that are likely to recur or are at risk of such diseases judged by the investigator.
  6. Major cardiovascular disease
  7. Active hepatitis B and/or hepatitis C (HBV-DNA or HCV-RNA detectable by local laboratory, respectively).
  8. Patients with history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
  9. A history of allograft organ transplantation for solid tumor or allogeneic hematopoietic stem cell transplantation for B-NHL patients).
  10. Patients who are pregnant or lactating.

Locations

  • UCSF (UCSF) accepting new patients
    San Francisco California 94102 United States
  • Regents of the University of Colorado accepting new patients
    Aurora Colorado 80045 United States
  • University of Texas M.D. Anderson Cancer Center accepting new patients
    Houston Texas 77030 United States
  • Yale University accepting new patients
    New Haven Connecticut 06520- 8087 United States

Lead Scientist at UCSF

  • Bridget Keenan, PhD
    Dr. Keenan completed her MD and PhD at the Johns Hopkins University School of Medicine, where she focused on using cancer vaccines to overcome immune suppression in the tumor microenvironment in mouse models of pancreatic cancer. She completed her Internal Medicine residency and Hematology/Oncology fellowship at UCSF.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Antengene Biologics Limited
ID
NCT06028373
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 48 study participants
Last Updated